Patents Represented by Attorney Austin W. Zhang
-
Patent number: 8298547Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.Type: GrantFiled: December 9, 2009Date of Patent: October 30, 2012Assignee: Pfizer Vaccines, LLCInventors: Alan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
-
Patent number: 7871786Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.Type: GrantFiled: September 11, 2008Date of Patent: January 18, 2011Assignee: Sugen, Inc.Inventors: Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky
-
Patent number: 7645786Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.Type: GrantFiled: December 14, 2006Date of Patent: January 12, 2010Assignee: Pfizer Inc.Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
-
Patent number: 7618626Abstract: The present invention relates to a therapeutic method for the treatment of non-hematologic malignancies comprising administering anti-IGF-1R antibodies, particularly human anti-IGF-1R antibodies, to a patient, in conjunction with the administration of at least one other therapeutic agent. The invention further relates to pharmaceutical compositions comprising these antibodies and methods of using such compositions thereof for treatment.Type: GrantFiled: July 15, 2005Date of Patent: November 17, 2009Assignee: Pfizer IncInventors: Antonio Gualberto, Bruce D. Cohen, Carrie L. Melvin, M. Luisa Roberts
-
Patent number: 7592362Abstract: This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.Type: GrantFiled: January 4, 2007Date of Patent: September 22, 2009Assignee: Pfizer LimitedInventors: Nathan Anthony Logan Chubb, Mark Roger Cox, Jerome Sebastien Dauvergne, Richard Andrew Ewin, Christelle Lauret
-
Patent number: 7575746Abstract: The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention have been altered to comprise antibodies with one or more selected germline framework amino acid residues which replace one or more corresponding somatically mutated residues in the variable region of the unaltered antibody. The modification results in the framework region mutations converted to germline. The modification results in a reduced propensity for the antibody to elicit an immune response (reduced immunogenicity) following administration to a human subject.Type: GrantFiled: March 3, 2008Date of Patent: August 18, 2009Assignee: Pfizer Inc.Inventors: Bruce D. Cohen, Vahe Bedian
-
Patent number: 7371378Abstract: The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention have been altered to comprise antibodies with one or more selected germlne framework amino acid residues which replace one or more corresponding somatically mutated residues in the variable region of the unaltered antibody. The modification results in the framework region mutations converted to germline. The modification results in a reduced propensity for the antibody to elicit an immune response (reduced immunogenicity) following administration to a human subject.Type: GrantFiled: August 12, 2004Date of Patent: May 13, 2008Assignee: Pfizer Inc.Inventors: Bruce D. Cohen, Vahe Bedian
-
Patent number: 7160888Abstract: This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R1, and R4 through R7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.Type: GrantFiled: July 28, 2004Date of Patent: January 9, 2007Assignee: Warner Lambert Company LLCInventors: Douglas S. Johnson, Joseph Thomas Repine, Andrew David White
-
Patent number: 7119201Abstract: The present invention relates to triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione; metalloproteinase inhibitors of the formula wherein X, A, Y, B, G, W, and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.Type: GrantFiled: April 28, 2003Date of Patent: October 10, 2006Assignee: Pfizer IncInventors: Lawrence Alan Reiter, Kevin Daniel Freeman-Cook
-
Patent number: 6998249Abstract: The present invention provides materials and methods for predicting the in vivo toxicity of a given compound. For example, the invention comprises conducting at least three distinct assays in parallel to provide information about three distinct parameters of cytotoxicity of a chemical in a given target cell, which information is useful for predicting in vivo cytotoxicity.Type: GrantFiled: June 2, 2000Date of Patent: February 14, 2006Assignee: Pharmacia & Upjohn CompanyInventors: James M. McKim, Gary L. Cockerell
-
Patent number: 6939560Abstract: The present invention provides a pharmaceutical composition which is substantially free of unpleasant tastes and orally administrable which comprises: (a) an active medicament, (b) an inner coating layer comprising an oil substance having a melting point at a range of from about 50° C. to about 100° C., (c) an outer coating layer comprising at least a polymeric substance.Type: GrantFiled: December 15, 2000Date of Patent: September 6, 2005Assignee: Pharmacia & Upjohn CompanyInventors: Robert W. Shen, Gerald A. Walter
-
Patent number: 6740652Abstract: The present invention involves a method of treating an ophthalmic infection in a useful warm blooded mammal who is in need of such treatment which comprises topical administration of an ophthalmologically effective amount of an OXAZOLIDINONE.Type: GrantFiled: September 19, 2001Date of Patent: May 25, 2004Assignee: Pharmacia & Upjohn CompanyInventors: Robert J. Cochran, Charles W. Ford
-
Patent number: 6602868Abstract: The invention provides methods and use of heterocyclic amines, and phenylazacycloalkane compounds, and their pharmacologically acceptable salts for the treatment of Restless Legs Syndrome (RLS).Type: GrantFiled: October 29, 2001Date of Patent: August 5, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Sylvia McBrinn, Richard Wayne Anderson
-
Patent number: 6562820Abstract: The invention is directed to a method of treatment or prevention of mastitis in mammals with known oxazolidinone anti-bacterial agents, either alone or in combination with exogenous lactoferrins.Type: GrantFiled: June 23, 2001Date of Patent: May 13, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Jeffrey L. Watts, Margaret S. Sanchez
-
Patent number: 6555548Abstract: The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of cabergoline-type compounds or a salt of said compound.Type: GrantFiled: May 30, 2002Date of Patent: April 29, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Robert B. McCall, Robert Clyde Marshall, David W. Robertson, Thomas M. Ashley
-
Patent number: 6538035Abstract: The present invention is a method of treating an mammal selected from the group consisting of humans and horses who has asthma, COPD or allergic rhinitis and is in need of such treatment by inhaling an anti-asthma, anti-COPD anti-allergic rhinitis effective amount, respectively, of a compound selected from the group consisting of tolterodine hydroxytolterodine and 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate and pharmaceutically acceptable salts thereof.Type: GrantFiled: October 23, 2001Date of Patent: March 25, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Per-Goran Gillberg, Staffan Sundquist, Sue K. Cammarata
-
Patent number: 6531139Abstract: The present invention provides a novel pharmaceutical composition based on the use of a particular oil phase which comprises a lipophilic, pharmaceutically active agent, a mixture of diglyceride and monoglyceride in a ratio of from about 9:1 to about 6:4 by weight (diglyceride:monoglyceride) wherein the diglyceride and monoglyceride are mono- or di- unsaturated fatty acid esters of glycerol having sixteen to twenty-two carbon chain length, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants. The composition is in a form of self-emulsifying formulation which provides high concentration and high oral bioavailability for lipophilic compounds.Type: GrantFiled: July 27, 1998Date of Patent: March 11, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Ping Gao, Walter Morozowich
-
Patent number: 6503920Abstract: This invention discloses new uses and treatments involving cabergoline, pramipexole and new combinations of cabergoline plus pramipexole used to treat patients. Here we disclose the use of cabergoline or pramipexole to treat PSP and MSA. Also disclosed is a combination treatment of cabergoline and pramipexole provided concurrently to a patient in need thereof for the treatment of various central nervous system diseases and in particular for the treatment of Parkinson's Disease (PD), but also for PSP and MSA.Type: GrantFiled: November 6, 2000Date of Patent: January 7, 2003Assignee: Pharmacia & Upjohn CompanyInventor: Baltazar Gomez-Mancilla
-
Patent number: 6458820Abstract: The present invention provides the use of pramipexole as a neuroprotective agent.Type: GrantFiled: November 3, 2000Date of Patent: October 1, 2002Assignee: Pharmacia & Upjohn CompanyInventors: Edward Dallas Hall, Philip F. Von Voigtlander, Frank A. Rohde
-
Patent number: 6448258Abstract: The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of heterocyclic amine-type compounds or a salt of any said compound.Type: GrantFiled: April 17, 2001Date of Patent: September 10, 2002Assignee: Pharmacia & Upjohn CompanyInventors: Robert B. McCall, Robert Clyde Marshall, David W. Robertson, Thomas M. Ashley